IR&MEDIA

NEWS

REV-MED Participates in BIO USA 2025, Accelerating Entry into the Global Autologous Biologics Market

관리자
8 Jun 2026
Views 214

ddcc7b2c3df2d.png

[Medical Observer Reporter Hyung-Joo Shin] REV-MED announced its participation in BIO USA 2025, marking a significant step toward expanding its presence in the global autologous biologics market.

Following its efforts to establish a foothold in Latin American and Central American markets, the company plans to use BIO USA 2025 as a platform to further expand into North America and strengthen its global influence.

As its initial target within the global autologous biologics sector, REV-MED has identified the Orthobiologics market as a key strategic focus.

Leveraging its proprietary autologous biologics extraction technologies, the company aims to address the growing global demand for regenerative medicine and orthopedic applications.

REV-MED’s flagship platforms, including NovaStem BC and NovaStem BMAC, are recognized for their ability to precisely separate and concentrate biological components from blood and bone marrow, enabling utilization across a variety of clinical settings.

The global Orthobiologics market is projected to grow from approximately USD 5.76 billion in 2025 to USD 8.28 billion by 2035, representing a compound annual growth rate (CAGR) of approximately 3.7%.

This growth is being driven by increasing demand for treatments related to sports injuries, musculoskeletal disorders, and aging populations. Regenerative medicine technologies, particularly platelet-rich plasma (PRP) and bone marrow-derived therapies, are creating new treatment opportunities within the field.

North America currently represents the largest Orthobiologics market, accounting for approximately 47.78% of global market share. The region’s active adoption of advanced medical technologies and strong interest in regenerative medicine and tissue regeneration therapies make it a strategically important market for REV-MED.

The United States continues to lead the Orthobiologics sector through major healthcare institutions and research centers that drive clinical research and product development.

Having already established credibility through regulatory approvals in key international markets including Japan, China, and Europe, REV-MED plans to utilize BIO USA 2025 as an opportunity to expand collaborations with healthcare professionals, researchers, and business partners throughout North America.

The company expects to broaden its business beyond Orthobiologics into the wider autologous biologics sector while strengthening its leadership position in the global regenerative medicine industry through its proprietary technologies and competitive advantages.

Source: Medical Observer

0 0